Filing Flows › Iovance Biotherapeutics (IOVA) › Q2 2026 › vs Q1 2026
Iovance Biotherapeutics (IOVA) Q2 2026 vs Q1 2026 (quarter over quarter)
Iovance Biotherapeutics's revenue rose $27.9M (+39%) from $71.4M in Q1 2026 to $99.3M in Q2 2026. The biggest changes: Amtagvi +$30.5M (+51%); PROLEUKIN −$2.6M (-23%).
Iovance Biotherapeutics, Q2 2026: revenue $99.3M (+66% year over year), operating margin -52.3%, net loss $47.3M, operating cash flow −$60.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Amtagvi | $90.7M | $60.2M | $30.5M | +51% |
| PROLEUKIN | $8.6M | $11.2M | −$2.6M | -23% |
| Revenue | $99.3M | $71.4M | $27.9M | +39% |
| Other income, net | $3.2M | $1.3M | $1.9M | +141% |
| Income tax benefit | $1.4M | $665K | $708K | +106% |
| Net loss | $47.3M | $79.0M | −$31.7M | -40% |
| Costs & expenses | $151M | $152M | −$1.3M | -0.8% |
| Operating costs | $151M | $152M | −$1.3M | -0.8% |
| Cost of revenue | $43.6M | $42.5M | $1.1M | +3% |
| Research & development | $58.9M | $62.5M | −$3.6M | -6% |
| General & admin | $39.3M | $38.9M | $323K | +0.8% |
| Other operating costs | $9.5M | $8.5M | $961K | +11% |
| Operating cash sources | $76.4M | $86.2M | −$9.8M | -11% |
| Depreciation & amortization | $3.8M | $2.8M | $961K | +34% |
| Share-based compensation | $11.7M | $11.3M | $464K | +4% |
| Cash used in operations | $60.8M | $72.1M | −$11.2M | -16% |
| Net loss absorbed | $47.3M | $79.0M | −$31.7M | -40% |
| Working capital & other | $29.0M | $7.1M | $21.9M | +308% |
Questions
How much did Iovance Biotherapeutics's revenue grow quarter over quarter in Q2 2026?
Iovance Biotherapeutics's revenue rose $27.9M (+39%) from $71.4M in Q1 2026 to $99.3M in Q2 2026.
What drove Iovance Biotherapeutics's revenue change in Q2 2026?
Amtagvi +$30.5M (+51%); PROLEUKIN −$2.6M (-23%).